Fig. 2From: Add-on neurological benefits of antiviral therapy in HCV patients with chronic kidney disease — a nationwide cohort study a All-cause mortality survival curves in the treated and untreated cohorts; b incidence density of hemorrhagic stroke between the treated and untreated cohortsBack to article page